Literature DB >> 9918165

Morphologic and biologic changes of experimentally induced cholesteatoma in Mongolian gerbils with anticytokeratin and lectin study.

C S Kim1, J W Chung.   

Abstract

HYPOTHESIS: Aural cholesteatoma has different morphologic and biologic characteristics from the normal epithelial cells.
BACKGROUND: The exact pathophysiology of aural cholesteatoma has not been proved. There are certain factors that can be involved in the development of the aural cholesteatoma, which makes it necessary to find the morphologic and biologic changes in aural cholesteatoma.
METHODS: The animal model of aural cholesteatoma was induced in gerbils with the external auditory canal (EAC) ligation method. Using immunohistochemical method, the distribution of cytokeratin and the binding patterns of lectin were observed to show the biologic and morphologic changes that take place in aural cholesteatomas.
RESULTS: The successful induction rate was 86.7%. The cytokeratin distribution of aural cholesteatoma was similar to that of EAC but different from that of the middle ear mucosa. The cytokeratin distribution in the cholesteatoma did not change with the different duration of EAC ligation. The results of the lectin-binding study indicate that the mucin-type cells are mainly distributed in the suprabasal cells of aural cholesteatoma and that the basal cells of cholesteatoma lack a D-galactosyl sugar residue.
CONCLUSION: This study suggests that the origin of aural cholesteatoma may be the external auditory canal epidermal cells, and the characteristics of these cells do not change once the cholesteatoma develops. This study also suggests that cholesteatoma has different biologic nature from that of the normal epithelial cell, especially in the basal cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918165

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  8 in total

1.  In vivo over-expression of KGF mimic human middle ear cholesteatoma.

Authors:  Tomomi Yamamoto-Fukuda; Naotaro Akiyama; Yasuaki Shibata; Haruo Takahashi; Tohru Ikeda; Takehiko Koji
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-20       Impact factor: 2.503

2.  Pathogenesis of middle ear cholesteatoma: a new model of experimentally induced cholesteatoma in Mongolian gerbils.

Authors:  Tomomi Yamamoto-Fukuda; Yoshitaka Hishikawa; Yasuaki Shibata; Toshimitsu Kobayashi; Haruo Takahashi; Takehiko Koji
Journal:  Am J Pathol       Date:  2010-04-22       Impact factor: 4.307

3.  Cytokeratin expression pattern in congenital and acquired pediatric cholesteatoma.

Authors:  Ewa Olszewska; Jürgen Lautermann; Can Koc; Matthias Schwaab; Stefan Dazert; Henning Hildmann; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-08       Impact factor: 2.503

Review 4.  Etiopathogenesis of cholesteatoma.

Authors:  Ewa Olszewska; Mathias Wagner; Manuel Bernal-Sprekelsen; Jörg Ebmeyer; Stefan Dazert; Henning Hildmann; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-27       Impact factor: 2.503

Review 5.  Animal models of middle ear cholesteatoma.

Authors:  Tomomi Yamamoto-Fukuda; Haruo Takahashi; Takehiko Koji
Journal:  J Biomed Biotechnol       Date:  2011-04-06

Review 6.  Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives.

Authors:  Mahmood A Hamed; Seiichi Nakata; Ramadan H Sayed; Hiromi Ueda; Badawy S Badawy; Yoichi Nishimura; Takuro Kojima; Noboru Iwata; Ahmed R Ahmed; Khalid Dahy; Naoki Kondo; Kenji Suzuki
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-21       Impact factor: 3.372

Review 7.  Hyperproliferation markers in ear canal epidermis.

Authors:  João Daniel Caliman e Gurgel; Siqueira Barbosa Pereira; Adriana Leal Alves; Fernando Quintanilha Ribeiro
Journal:  Braz J Otorhinolaryngol       Date:  2010 Sep-Oct

Review 8.  Some considerations about acquired adult and pediatric cholesteatomas.

Authors:  Cristina Dornelles; Sady S da Costa; Luíse Meurer; Cláudia Schweiger
Journal:  Braz J Otorhinolaryngol       Date:  2005-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.